New data on multiple targeted agents and evolving diagnostic frameworks highlight progress in classifying and treating EGFR PACC–mutated NSCLC.
|Videos|April 28, 2016
Kathryn Ciccolini Discusses the CREAM Principles to Manage Dermatologic AEs
Author(s)Kathryn Ciccolini, RN, BSN, OCN, DNC
Kathryn Ciccolini, RN, BSN, OCN, DNC, Memorial Sloan Kettering Cancer Center, discusses the concept she developed to manage dermatologic adverse events for patients with cancer.
Advertisement
Kathryn Ciccolini, RN, BSN, OCN, DNC, Memorial Sloan Kettering Cancer Center, discusses the concept she developed to manage dermatologic adverse events for patients with cancer.
Many patients who are taking anticancer therapies experience dermatologic adverse events, so Ciccolini wanted to create an interdisciplinary approach that could help manage and treat these side effects. And so, the CREAM (communication, referral, education, encouragement, assessment, management and monitoring) principles were born.
For more information, visit
<<<
Advertisement
Related to this article
Edward B. Garon, MD, MS, details how frontline therapy shapes sequencing in relapsed/refractory EGFR-mutated non–small cell lung cancer.
Watch a highlight reel of breast cancer data from ASCO 2026 that experts anticipate will have the biggest impact on the field.
Experts shared the key data that stood out in GU oncology at the 2026 ASCO Annual Meeting.
Experts shared the key data that stood out in hematologic oncology at the 2026 ASCO Annual Meeting.
The TRIPP-FFX trial met its primary end points of local disease control and safety with P-32 microparticles plus FOLFIRINOX in pancreatic adenocarcinoma.
Readouts across LBCL, relapsed/refractory myeloma, and CALR-mutated myelofibrosis anchored the hematology data presented at EHA 2026.
Advertisement
Advertisement
Trending on OncLive
1
The OncFive: Top Oncology Articles for the Week of 7/19
2
Epcoritamab Misses Sole US Primary End Point of Overall Survival in R/R DLBCL
3
EGFR PACC Mutations Define a Distinct NSCLC Subclass With Growing Treatment Options
4
Frontline Choice Anchors Sequencing Decisions in EGFR-Mutated NSCLC
5